MetaVia Inc. (NASDAQ:MTVA) Short Interest Update

MetaVia Inc. (NASDAQ:MTVA) was the target of a large growth in short interest during the month of July. As of July 15th, there was short interest totaling 344,566 shares, a growth of 177.8% from the June 30th total of 124,038 shares. Based on an average daily volume of 1,041,508 shares, the days-to-cover ratio is currently 0.3 days. Approximately 6.7% of the shares of the company are sold short.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of MetaVia in a research report on Tuesday, July 21st. HC Wainwright reissued a “buy” rating on shares of MetaVia in a report on Friday, July 10th. Finally, Wall Street Zen upgraded MetaVia to a “sell” rating in a research note on Saturday, June 20th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $20.00.

MetaVia Stock Down 1.4%

Shares of NASDAQ:MTVA traded down $0.02 during trading on Tuesday, hitting $1.43. 54,636 shares of the company were exchanged, compared to its average volume of 1,835,784. The business’s 50 day moving average is $2.01 and its 200-day moving average is $2.04. The company has a market capitalization of $7.38 million, a P/E ratio of -0.28 and a beta of 0.97. MetaVia has a 1-year low of $0.97 and a 1-year high of $19.03.

MetaVia (NASDAQ:MTVA) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03). As a group, sell-side analysts anticipate that MetaVia will post -2.78 earnings per share for the current year.

Institutional Trading of MetaVia

An institutional investor recently bought a new position in MetaVia stock. Virtu Financial LLC bought a new position in shares of MetaVia Inc. (NASDAQ:MTVA) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned about 0.14% of MetaVia at the end of the most recent reporting period. 1.37% of the stock is currently owned by institutional investors.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.